Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 632-640

  Pagani, O ^h   O'Neill, A ^a   Castiglione, M ^b   Gelber, R D ^a   Goldhirsch, A ^b,k,l   Rudenstam, C M ^c   Lindtner, J ^d   Collins, J ^e   Crivellari, D ^f   Coates, A ^g   Cavalli, F ^h   Thurlimann B ⁱ   Simoncini, E ^j   Fey, M ⁱ   Price, K ^a   Senn, H J ⁱ   Castiglione Gertsch, M ^b   Gusterson, B ^b   Bettelheim, R ^b   Reed, R ^b   Gusset, H ^b   Geiser, K ^b   Hurny Ch ^b   Bernhard, J ^b   Hangartner A ^b   Maibach, R ^b   Pedowski, R ^b   Gelber, R ^a   Peterson, H ^a   Zelen, M ^a   Isley, M ^m   Hinkle, R ^m   Kay, R G ⁿ   Holdaway, I M ⁿ   Harvey, V J ⁿ   Jagusch, M F ⁿ   Neave, L ⁿ   Mason, B M ⁿ   Evans, B ⁿ   Benjamin, C S ⁿ   Carter, J F ⁿ   Gillman, J C ⁿ   Mack, D ⁿ   Benson Cooper, D ⁿ   Monfardini, S ^f   Galligioni, E ^f   Buonadonna, A ^f   Massarut, S ^f   Rossi, C ^f   Candiani, E ^f   Carbone, A ^f   Volpe, R ^f   Trovo, M G ^f   Roncadin, M ^f   Santini, G F ^f   Villalta, D ^f   Coran, F ^f   Morassut, S ^f   Marini, G ^j   Marpicati, P ^j   Zaniboni, A ^j   Sartori, U ^j   Barni, A ^j   Cerutti, L ^j   Alghisi, A ^j   Raffaglio, E ^j   Garattini, M P ^j   Albertini, A ^j   Grigolato, P ^j   Morassi, L ^j   Bergonzini, R ^j   Lauriola, C ^j   Gudgeon, A ^o   Dent, D M ^o   Tiltman, A ^o   Hacking, A ^o   Dowdle, E ^o   Steynor, P ^o   Toop, J ^o   Schnuren H G ^p   Mosny, D ^p   Bender, H G ^p   Bojar, H ^p   Veronesi, A ^q   Foladore, S ^q   Pamich, G ^q   Bianchi, G ^q   Torretta, A ^q   Wallgren, A ^c   Persson, S ^c   Mattsson, J ^c   Cahlin, E ^c   Hafstrom L O ^c   Holmberg, S ^c   Hultborn, R ^c   Colldahl Jaderstrom G ^c   Gustavsson, B ^c   Carlsson, G ^c   Ivarsson, L ^c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b International Breast Cancer Study Group   (Switzerland)

^c W Swedish Breast Cancer Study Group   (Sweden)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h OSPEDALE SAN GIOVANNI   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j SPEDALI CIVILI   (Italy)

^k EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^l Ospedale Civico Lugano   (Switzerland)

^m FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁿ Auckland Breast Cancer Study Group   (New Zealand)

^o UNIVERSITY OF CAPE TOWN   (South Africa)

^p HEINRICH HEINE UNIVERSITY   (Germany)

^q Presidio Ospedaliero   (Italy)

more..

Author keywords

Adjuvant chemotherapy; Amenorrhoea; Breast cancer; Premenopausal

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE;

EID: 0032055890     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10036-3     Document Type: Article

References (23)

1. 1. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 1989, 16, 425-436.
2. 2. Brincker H, Rose C, Rank F. et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 1987, 5, 1771-1778.
3. 3. Reyno LM, Levine MN, Skingley P, Arnold A, Zahra HA. Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 1993, 29A, 21-23.
4. 4. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Annals Oncol 1990, 1, 183-188.
5. 5. Bianco AR, Del Mastro L, Gallo C, et al. Prognostic role of amenorrhoea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991, 63, 799-803.
6. 6. Fisher B, Sherman B, Rockette H, et al. 1-Phenylanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of DFS with depression of ovarian function. Cancer 1979, 44, 847-857.
7. 7. Collichio F, Pandya K. Amenorrhoea following chemotherapy for breast cancer: effect on disease-free survival. Oncol 1994, 8, 45-52.
8. 8. Bines J, Oleske D, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14, 1718-1729.
9. 9. Anderson JR, Cain KC, Gelber RD, Gelman RS. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treatment Reports 1985, 69, 1139-1146.
10. 10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958, 53, 457-481.
11. 11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977, 35, 1-39.
12. 12. Cox DR. Regression models and life tables (with discussion). JR Stat Soc B (Methodology) 1972, 34, 187-220.
13. 13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24000 deaths among 75000 women. Lancet 1992, 339, 1-15; 71-85.
14. 14. Bonadonna G, Valagussa P, Rossi A, et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985, 5, 95-115.
15. 15. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 1995, 332, 901-906.
16. 16. Richards MA, O'Reilly SM, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/ Manchester Trial. J Clin Oncol 1990, 8, 2032-2039.
17. 17. Padmanabhan N, Howell A, Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986, II, 411-414.
18. 18. Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFp) or CMFp plus tamoxifen compared with CMF for premenopausal breast cancer patients: an Eastern Cooperative Oncology Group Trial. Cancer 1990, 65, 200-206.
19. 19. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985, 45, 4454-4459.
20. 20. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 1988, 319, 677-683.
21. 21. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of peri-operative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989, 320, 491-496.
22. 22. Musgrove E, Sutherland L. Steroids, growth factors, and cell cycle controls in breast cancer. In Lippman M and Dickson R, eds. Regulatory Mechanisms in Breast Cancer. Boston, Kluwer Academic Publishers, 1991, 305-331.
23. 23. Nissen-Meyer R. Primary breast cancer: the effect of primary ovarian irradiation. Annals Oncol 1991, 2, 343-346.